K0706

DRUG5 trials

Sponsors

Sun Pharma Advanced Research Company Limited

Conditions

CML, RefractoryCML, RelapsedEarly Parkinson DiseaseHealthyParkinson Disease

Phase 1

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

CompletedNCT02970019

Sun Pharma Advanced Research Company LimitedParkinson Disease

Start: 2017-03-30End: 2019-05-28Updated: 2020-03-31

Bioavailability Study of K0706 in Healthy Subjects

CompletedNCT03316820

Sun Pharma Advanced Research Company LimitedHealthy

Start: 2017-10-28End: 2017-11-21Updated: 2019-05-03

To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers

CompletedNCT03445338

Sun Pharma Advanced Research Company LimitedHealthy

Start: 2018-04-15End: 2019-12-06Updated: 2020-01-14

Phase 2

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

TerminatedNCT03655236

Sun Pharma Advanced Research Company LimitedEarly Parkinson Disease

Start: 2019-02-18End: 2024-06-06Updated: 2025-07-25

Unknown Phase

Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments

Sun Pharma Advanced Research Company LimitedCML, Refractory, CML, Relapsed

Updated: 2026-04-15

Related Papers

Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents.

2025-07-18